Related Experiment Video
Updated: Jun 11, 2025

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
How to utilize current guidelines to manage patients with cancer at high risk for heart failure
Michelle Bloom1, Jose A Alvarez-Cardona1, Sarju Ganatra2
1Leon H. Charney Division of Cardiology, New York University School of Medicine, NYU Langone Health, New York, NY, USA.
Insights
Cancer survivors face increased risks of heart failure (HF) and cardiovascular disease (CVD). Early detection and prevention strategies, guided by European Society of Cardiology (ESC) guidelines, are crucial for managing these conditions in patients undergoing cancer therapy.
Area of Science:
- Cardio-Oncology
- Cardiovascular Disease in Cancer Survivors
Background:
- Cancer therapies improve survival but increase long-term cardiovascular disease (CVD) risks.
- Cardiovascular disease (CVD), including heart failure (HF) and cardiomyopathy (CM), is a leading cause of mortality in cancer survivors.
- European Society of Cardiology (ESC) guidelines offer a framework for managing cardiovascular (CV) health during and after cancer treatment.
Purpose of the Study:
- To summarize key aspects of the ESC Cardio-Oncology (CO) guidelines relevant to HF clinicians.
- To emphasize risk stratification, early detection, and prevention of CM and HF in cancer patients.
- To highlight the role of guideline-directed medical therapy (GDMT) in managing HF in this population.
Main Methods:
- Case study utilization to illustrate ESC guideline principles.
- Focus on risk stratification, early detection, and prevention strategies.
- Review of GDMT applications for HF in cancer patients.
Main Results:
- Cancer patients require vigilant CV monitoring due to treatment-related risks.
- Proactive risk stratification and early detection of CM/HF are essential.
- ESC guidelines provide a comprehensive approach to CV care throughout the cancer journey.
Conclusions:
- Integrating CO principles into HF clinical practice is vital.
- Timely intervention and GDMT can mitigate HF morbidity and mortality in cancer patients.
- Adherence to ESC guidelines improves outcomes for cancer survivors at risk of HF.
Abstract:
Heart failure (HF) in patients with cancer is associated with high morbidity and mortality. The success of cancer therapy has resulted in an exponential rise in the population of cancer survivors, however cardiovascular disease (CVD) is now a major life limiting condition more than 5 years after cancer diagnosis [Sturgeon, Deng, Bluethmann, et al 40(48):3889-3897, 2019]. Prevention and early detection of CVD, including cardiomyopathy (CM) and HF is of paramount importance. The European Society of Cardiology (ESC) published guidelines on Cardio-Oncology (CO) [Lyon, López-Fernández, Couch, et al 43(41):4229-4361, 2022] detailing cardiovascular (CV) risk stratification, prevention, monitoring, diagnosis, and treatment throughout the course and following completion of cancer therapy. Here we utilize a case to summarize aspects of the ESC guideline relevant to HF clinicians, with a focus on risk stratification, early detection, prevention of CM and HF, and the role for guideline directed medical therapy in patients with cancer.
More Related Videos
Related Concept Videos
Heart Failure V: Nursing Interventions
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Cardiomyopathy VI: Nursing Management
Heart Failure IV: Classification and Diagnostic Evaluation
Cardiomyopathy V: Interprofessional Care

